|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C32H40BrN5O5.CH4O3S |
|||
| Molecular Weight | 750.7 | CAS No. | 22260-51-1 | |
| Solubility (25°C)* | In vitro | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Biological Activity
| Description | Bromocriptine mesylate is a dopamine receptor agonist with a Ki of 12.2 nM for D3 receptor and D2 receptor and a Ki of 1659 nM, 59.7 nM, 1691 nM for D1 receptor, D4 receptor, and D5 receptor, respectively. Bromocriptine mesylate is used in the treatment of Parkinson's disease, hyperprolactinemia-associated dysfunctions, and acromegaly. | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Targets |
|
||||||||||
| In vitro | Bromocriptine dose-dependently reduces the number of OH radicals. [1] Bromocriptine has a strong scavenging effect on the 5,5-dimethyl-1-pyrroline-N-oxide hydroxide signal produced from Fenton's reaction. Bromocriptine also attenuates the stable free radical diphenyl-p-picrylhydrazyl signal. [2] |
||||||||||
| In vivo | Bromocriptine (5 mg/kg, i.p., 7 days) completely protects against the decrease in mouse striatal dopamine and its metabolites induced by intraventricular injection of 6-hydroxydopamine after intraperitoneal administration of desipramine. [1] Bromocriptine (2.5 mg/kg, i.p., daily for 3 days) significantly reduces autooxidation of brain homogenates collected from rats. [2] Bromocriptine (12.5 mg/kg) produces mild dyskinesia over the course of the study that is significantly less severe than in the L-dopa-treated group in the MPTP-treated marmoset. Bromocriptine, has a lesser tendency than L-dopa to produce dyskinesia while similarly improving motor performance in drug-naive MPTP-treated marmosets. [3] Bromocriptine (10 μM and 10 mg/kg i.p.) blocks .OH formation caused by MPTP in vitro (20 μM) and in vivo (30 mg/kg i.p.) in mice. Bromocriptine reduces an MPTP-induced increase in the activity of catalase and superoxide dismutase in substantia nigra on the seventh day. Bromocriptine blocks MPTP-induced behavioral dysfunction as well as glutathione and dopamine depletion, indicating its potent neuroprotective action. [4] |
Protocol (from reference)
References
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.